Department of Medical Microbiology, School of Basic Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Clinical Laboratory, Weifang Second People's hospital, Weifang, Shandong, China.
Front Cell Infect Microbiol. 2024 Oct 10;14:1454096. doi: 10.3389/fcimb.2024.1454096. eCollection 2024.
This study aims to develop a novel diagnostic approach using the recombinase aided amplification-lateral flow dipstick(RAA-LFD) assay for the distinction of (MTB) and (MAC), enabling rapid and convenient as well as accurate identification of them in clinical samples.
Our study established a duplex RAA-LFD assay capable of discriminating between MTB and MAC. Based on the principles of RAA primer and probe design, specific primers and probes were developed targeting the MTB and the MAC separately. Optimization of reaction time points and temperatures was conducted, followed by an evaluation of specificity, sensitivity, and reproducibility. The established detection method was then applied to clinical samples and compared with smear microscopy, liquid culture, LAMP, and Xpert/MTB RIF in terms of diagnostic performance.
The complete workflow allows for the effective amplification of the MTB and MAC target sequences at constant 37°C within 20min, and the amplification products can be visually observed on the LFD test strip. This method exhibits high specificity, showing no cross-reactivity with nucleic acids from , and common respiratory pathogens. It also demonstrates high sensitivity, with a detection limit as low as 10 CFU/mL. Additionally, the method's Coefficient of Variation (CV) is less than 5%, ensuring excellent repeatability and reliability. Furthermore, clinical performance evaluations, using Xpert/MTB RIF as the gold standard, demonstrated that the duplex RAA-LFD assay achieves a sensitivity of 92.86% and a specificity of 93.75%. It is also noteworthy that the assay exhibits considerable diagnostic efficacy in smear-negative patients.
Our study introduces a rapid, specific, and sensitive duplex RAA-LFD assay for the discriminatory diagnosis of MTB and MAC. This method represents a significant advancement in the field of infectious disease diagnostics, offering a valuable tool for rapid detection and management of MTB and MAC infections. The implementation of this approach in point-of-care settings could greatly enhance TB control and prevention efforts, especially in resource-limited environments.
本研究旨在开发一种新的诊断方法,即重组酶辅助扩增-侧流层析试纸条(RAA-LFD)检测,用于区分结核分枝杆菌(MTB)和鸟分枝杆菌复合体(MAC),能够快速、方便、准确地在临床样本中识别它们。
本研究建立了一种能够区分 MTB 和 MAC 的双重 RAA-LFD 检测方法。基于 RAA 引物和探针设计的原理,分别针对 MTB 和 MAC 设计了特异性引物和探针。优化了反应时间点和温度,然后评估了特异性、灵敏度和重现性。建立的检测方法随后应用于临床样本,并与涂片显微镜检查、液体培养、LAMP 和 Xpert/MTB RIF 的诊断性能进行了比较。
完整的工作流程允许在 37°C 下 20 分钟内有效地扩增 MTB 和 MAC 靶序列,扩增产物可在 LFD 测试条上进行可视化观察。该方法具有很高的特异性,与非结核分枝杆菌、和常见呼吸道病原体的核酸无交叉反应。它还表现出很高的灵敏度,检测限低至 10 CFU/mL。此外,该方法的变异系数(CV)小于 5%,确保了极好的重复性和可靠性。此外,使用 Xpert/MTB RIF 作为金标准的临床性能评估表明,双重 RAA-LFD 检测的灵敏度为 92.86%,特异性为 93.75%。值得注意的是,该检测方法在涂片阴性患者中具有相当的诊断效果。
本研究引入了一种快速、特异、灵敏的双重 RAA-LFD 检测方法,用于区分 MTB 和 MAC。该方法是传染病诊断领域的一项重大进展,为 MTB 和 MAC 感染的快速检测和管理提供了有价值的工具。在即时检测环境中实施这种方法可以极大地加强结核病控制和预防工作,特别是在资源有限的环境中。